Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gina McMullen Sr. PK Research Associate ISIS Pharmaceuticals, Inc.

Similar presentations

Presentation on theme: "Gina McMullen Sr. PK Research Associate ISIS Pharmaceuticals, Inc."— Presentation transcript:

1 Gina McMullen Sr. PK Research Associate ISIS Pharmaceuticals, Inc.
Ensuring Quality Management of PK Samples from Collection to Archival and Selecting the Right Biorepository for Your Needs Gina McMullen Sr. PK Research Associate ISIS Pharmaceuticals, Inc.

2 Objectives: Provide an overview of PK sample collection, processing, analysis, data reporting, and eventual archival. Identify considerations for protocol planning & Bioanalytical Lab selection to ensure integrity & accurate data reporting. Evaluate key aspects when choosing a commercial Biorepository for long term storage (of PK samples), in order to maintain integrity for potential future use, and ultimately benefit your drug development program in the long run.

3 Example of First Order Kinetics
What is PK? Pharmacokinetics (PK) is essentially the study of what the body does to a drug once it’s been administered by a chosen route (i.e. Topical, Enteral, or Parenteral). PK samples are collected at precise time points (per protocol) in a specific type of biological matrix (typically plasma) & subsequently analyzed for drug concentrations. Bioanalytical methods used to analyze these samples should be selective and sensitive, in order to construct an accurate concentration-time profile for your drug. Example of First Order Kinetics

4 The Importance of PK Samples
Pharmacokinetic (PK) samples play an integral role in the drug discovery & development process. PK concentration determinations not only allow for accurate characterization of the drug, but also assist in establishing the most effective dose regimen for the intended patient population. Ensuring these samples are properly collected, processed, analyzed, and eventually archived, is critical to the success of your drug.

5 General Overview of Drug Development Timelines
Studies published in 2003 indicate the cost to bring a new drug to market is around $800 million.[1,2] More recent studies estimate that cost to be as high as $2,000 million, depending upon the therapy or the company developing it. [3]

6 PK Component of Drug Development Timelines
Preclinical IND Enabling Toxicology Studies Up to1000 PK samples generated for analysis in a single IND enabling Toxicology study (nonhuman primate study) Up to 1500 PK samples generated for analysis in a single Phase 1, FIH, SAD/MAD study design (35-40 collected per patient) Phase 1, First in Human Studies Around PK samples generated from a single Phase 2A/2B study depending upon number of patients enrolled (25-30collected per patient) Phase 2A/2B Studies 1000+ PK samples generated from a Phase 3 study, but only around 5-10 collected per patient (increased # patients enrolled) Phase 3 Studies Time to Market

7 General Considerations
The Importance of proper PK sample collection, processing, reporting, and eventual archival

8 Overview of PK Sample Collection to Data Reporting
Pack sufficient dry ice in shipping container to ensure samples won’t thaw in event of delays. Two transfer tubes labeled identically: 1) Primary Aliquot for initial analysis 2) Duplicate Aliquot as a backup Purple topped EDTA collection tube Use validated methods for PK analysis under GLP compliance to ensure quality final data. Centrifuge Freeze Sample Log-In Ship to PK Lab for Analysis Analyze samples and report data Split into 2 equal aliquots Collect Sample i.e. 1500g for 15 4oC Ensure frozen immediately at appropriate temperature (i.e. -80oC) Proper identification at PK Lab is essential to accurate data reporting

9 PK Life Cycle Protocol Planning for Sample Collection PK Analysis
Study Considerations in order to ensure sample viability for future use Protocol Planning for Sample Collection Select optimum time points for drug characterization and identify in the protocol Communicate sample collection & processing expectations Type of collection tube (i.e. K2EDTA) Centrifugation speed, time, & temperature Amount to be apportioned to separate transfer tubes Specify information contained on tube labels Importance of assigning primary & duplicate aliquots for sample analysis availability Temperature for storage PK Analysis Ensure bioanalytical method has been validated prior to analysis Verify samples clearly identified at time of collection and are correctly reported in final data set Eventual Sample Archival Proper handling & management will allow samples to be utilized for additional analyses in the future if needed

10 Important Roles in Clinical PK Studies
Clinical Site Ensure protocol is followed and samples are properly identified at time of collection. Central Lab Preparation of PK Kits for Clinical site, including collection tubes & labels. Collate samples from multiple Clinical sites for shipment to designated PK Lab: Initial sample identifier reconciliation. Potential shipment directly to Biorepository. PK Lab Maintain information provided by Central Lab through analysis to preserve integrity of samples and ensure quality concentration data. Additional sample identifier reconciliation if needed. Subsequent shipment to BioRepository upon completion of analysis and final data submission. BioRepository Retain value of samples by ensuring proper storage for potential future use.

11 Bioanalytical Considerations during Protocol Planning
Matrix Selection Clinical: typically plasma or urine, occasionally tissue biopsies Preclinical: typically tissue, plasma, and urine for initial IND enabling studies Species selection (i.e. rodent, non-human primate, canine, etc.) Select appropriate type of assay to analyze PK samples in specified matrix LC/MS CE Ligand Binding Assay (ELISA)

12 Additional Considerations
Select appropriate bioanalytical facility for future PK sample analysis Ensure viable assay for concentration determination and efficient method transfer Establish sample collection, stability & storage requirements Anticoagulant to support analysis Detailed Processing instructions Transfer tube type (i.e. polypropylene vs. polystyrene, etc) Labels that will adhere to these tubes during freezing process Storage temperature & light sensitivity considerations to prevent degradation Limit number of freeze/thaw cycles to maintain sample viability

13 PK Study Considerations
For Clinical Trials, identify suitable central lab to ensure adequate supervision of clinical sites, sample management, & subsequent shipment to PK lab for analysis Preparation of sample collection kits, forms, labels, supplies, etc. For Preclinical Studies, ensure chosen In-Life facility can employ proper collection/processing/shipping/ and documentation technique. Proper information to be included on sample label (based on protocol) to ensure accurate identification for future use Requirements typically include the following: Protocol Accession # barcode Patient/Animal # Collection Date & Time (and/or Study Day & Time point per the protocol) Matrix type (plasma, urine, etc.) Aliquot assignment (primary vs. duplicate)

14 Documentation of Proper PK Sample Collection in a Clinical Trial
Complete and check all the information on the Laboratory Requisition Form IMPORTANT Ensure the Laboratory Requisition Form is complete and legible. If an error is made, strike-through the wrong information without obscuring the original entry, correct it, sign and date the change. Once completed, this form must be faxed to the Central Lab the day of sample collection. This is for tracking purposes. Please use the forms as follows: Investigator Information Barcode Label Visit information Patient information and sampling information Airway Bill Number and comments Number of specimens collected/ name, signature and date Send the white copy of the form with ambient specimens to Central Lab. Send the yellow copy of the form with frozen specimens to Central Lab. Retain the pink copy at clinical site.

15 Shipment Details Current address of PK facility plus contact information for individual who will be responsible for sample receipt Especially important when procuring specialized shipping permits. Detailed shipping manifest Preferably electronic to be populated with electronic data Temperature of sample shipment (wet vs. dry ice) Estimated shipping schedule (i.e. batching samples based on collection time points) Preferred courier for shipping (company who will ensure temperature is maintained throughout process & will re-fill ice if shipment is delayed) Tracking # allowing you to check status of shipment on-line

16 Sample Log-In Upon arrival at PK Lab
Notification to sponsor of safe receipt Sample log-in (discrepancy reconciliation between tube label & manifest) LIMS (Laboratory Information Management System) for internal sample tracking at PK lab

17 Sample Analysis & Data Reporting
Use validated method for analysis Proper handling of samples during analysis can prevent contamination If insufficient volume in primary aliquot use duplicate (ensure accurate identification and reporting). Ensure sample identifier information is accurately reported in the final data (i.e. tracking system) Can also be used as a manifest for shipping to selected off-site Biorepository QC/QA review of data and finalization of report Watch for anomalous concentration values which might otherwise be explained by incorrectly reported sample identifiers or contamination.

18 General Considerations
Choosing the Right Biorepository for long term storage needs

19 Key Traits to consider:
Interaction Identification Inventory Invoicing Integrity

20 Interaction (ensuring quality communication with your chosen Biorepository):
Communicate with Biorepository to ensure they can accommodate proper storage requirements: Optimal storage temperature (i.e. < -80oC) Light sensitivity concerns Length of time for storage requirements: Minimum amount of time for which samples need to be stored? Maximum amount of time they are allowed to be stored? What is your established Long Term Matrix Stability for this compound? How does that compare with industry guidance?

21 Interaction (cont.) Shipping considerations to Biorepository
Ensure constant temperature in shipment Clearly labeled sample tubes Accurate shipping manifest, (preferably electronic), which can easily be linked back to information on tube label Have Biorepository coordinate with Analytical facility to ensure safe & timely shipment of your PK samples

22 Identification (being able to properly identify a specific sample if/when needed):
Sample identifiers - how will facility be able to locate samples if needed in the future? Do they affix a specific label upon arrival at their facility during initial log-in of the samples? Do they have an in-house tracking system? If so, what type? (Paper, electronic, etc.) Policies on discrepancy resolution if samples arrive and labels don’t match with the shipping manifest. Additional cost to sponsor? Utilize PK lab to prepare shipping documents and QC labels prior to sending for long term storage?

23 Inventory (knowing what you’re storing and how much):
Double check policies re. sample inventory: Can sample information be accessed on-line? Does this feature result in additional charges (i.e. only certain individuals can access )? Will hard copy of inventory be sent? If so, how often? Monthly, quarterly, annually? Determine in advance how long samples should be retained (per industry guidelines & established LTS): Plan accordingly to have them disposed of at designated time points to ensure room for new samples.

24 Invoicing (budgeting accordingly for your Biorepository needs):
Know what you’re being charged for and how often: Per sample cost vs. entire shelf/freezer? Monthly bill vs. quarterly or annually? Hidden fees? Cost to locate/ship samples if needed? Cost to destroy samples once established LTS has been reached? In what capacity will you be utilizing your Biorepository? Batch shipping samples from ongoing studies for future analysis vs. long term storage once studies have completed? $

25 Integrity (acknowledging the value of these samples and ensuring the appropriate measures are in place to retain their value): Samples are irreplaceable and loss or damage to them would result in delays to your drug development program. To ensure sample integrity, your chosen facility should have measures in place to account for the following: Additional freezers for moving/ transitioning samples Back up generators for power failure In case of natural disaster are steps in place for additional generators/fuel/ manpower? Sufficient storage space to accommodate new freezers for future samples? Multiple locations to accommodate different shipping sites

26 …which can ultimately add value to your drug development program!
Take Home Message Maintaining sample integrity for potential future can be achieved by employing proper planning and diligence in the following areas: Sample Collection/Processing Sample Analysis Long Term Storage …which can ultimately add value to your drug development program!

27 References DiMasi J. "The value of improving the productivity of the drug development process: faster times and better decisions". Pharmacoeconomics 20 Suppl 3: 1–10. PMID DiMasi J, Hansen R, Grabowski H (2003). "The price of innovation: new estimates of drug development costs". J Health Econ 22 (2): 151–85. doi: /S (02) PMID Adams C, Brantner V. "Estimating the cost of new drug development: is it really 802 million dollars?". Health Aff (Millwood) 25 (2): 420–8. oi: /hlthaff PMID

28 We hope to see you in Philadelphia!
Biorepositories 2008 We hope to see you in Philadelphia! September 8 – 10, 2008

Download ppt "Gina McMullen Sr. PK Research Associate ISIS Pharmaceuticals, Inc."

Similar presentations

Ads by Google